{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T09:52:50Z","timestamp":1793440370466,"version":"4.5.0"},"reference-count":45,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2021,3,1]]},"DOI":"10.1001\/jamaoncol.2020.6973","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T11:08:24Z","timestamp":1610622504000},"page":"412","source":"Crossref","is-referenced-by-count":107,"title":["Comparison of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer"],"prefix":"10.1001","volume":"7","author":[{"given":"Lin","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland"},{"name":"Center for Drug Safety and Effectiveness, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Channing J.","family":"Paller","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwanhee","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina"},{"name":"Duke Clinical Research Institute, Duke University, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"De Felice","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Caleb","family":"Alexander","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland"},{"name":"Center for Drug Safety and Effectiveness, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otis","family":"Brawley","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland"},{"name":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"coi200103r3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41391-018-0078-1","article-title":"Non-metastatic castration resistant prostate cancer: a review of current and emerging medical therapies.","volume":"22","author":"Alpajaro","year":"2019","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"7","key":"coi200103r4","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJMra1701695","article-title":"Metastatic prostate cancer.","volume":"378","author":"Sartor","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"coi200103r5","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone\u2013sensitive prostate cancer.","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"issue":"10024","key":"coi200103r6","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"issue":"4","key":"coi200103r7","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer.","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"coi200103r8","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy.","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"coi200103r9","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol"},{"key":"coi200103r10","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.eururo.2019.08.006","article-title":"Abiraterone in \u201chigh-\u201d and \u201clow-risk\u201d metastatic hormone-sensitive prostate cancer.","volume":"76","author":"Hoyle","year":"2019","journal-title":"Eur Urol"},{"issue":"32","key":"coi200103r11","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer.","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"coi200103r12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer.","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"coi200103r16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"issue":"11","key":"coi200103r17","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations.","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"coi200103r18","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"2","key":"coi200103r20","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1002\/jrsm.1049","article-title":"Accounting for correlation in network meta-analysis with multi-arm trials.","volume":"3","author":"Franchini","year":"2012","journal-title":"Res Synth Methods"},{"key":"coi200103r22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves.","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"issue":"4","key":"coi200103r23","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1177\/1536867X1801700402","article-title":"Reconstructing time-to-event data from published Kaplan-Meier curves.","volume":"17","author":"Wei","year":"2017","journal-title":"Stata J"},{"key":"coi200103r24","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/1471-2288-11-61","article-title":"Network meta-analysis of survival data with fractional polynomials.","volume":"11","author":"Jansen","year":"2011","journal-title":"BMC Med Res Methodol"},{"key":"coi200103r25","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/rssb.2002.64.issue-4","article-title":"Bayesian measures of model complexity and fit (with discussion).","volume":"64","author":"Spiegelhalter","year":"2002","journal-title":"J Royal Stat Soc"},{"key":"coi200103r28","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1023\/A:1008929526011","article-title":"WinBUGS: a bayesian modelling framework: concepts, structure, and extensibility.","volume":"10","author":"Lunn","year":"2000","journal-title":"Stat Comput"},{"issue":"7-8","key":"coi200103r29","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis.","volume":"29","author":"Dias","year":"2010","journal-title":"Stat Med"},{"issue":"1","key":"coi200103r30","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/jrsm.v7.1","article-title":"Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis.","volume":"7","author":"Van Valkenhoef","year":"2016","journal-title":"Res Synth Methods"},{"key":"coi200103r32","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1080\/10618600.1998.10474787","article-title":"General methods for monitoring convergence of iterative simulations.","volume":"7","author":"Brooks","year":"1998","journal-title":"J Comput Graph Stat"},{"issue":"5","key":"coi200103r33","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1093\/annonc\/mdy072","article-title":"Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol.","volume":"29","author":"Sydes","year":"2018","journal-title":"Ann Oncol"},{"issue":"2","key":"coi200103r34","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","article-title":"Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.","volume":"14","author":"Gravis","year":"2013","journal-title":"Lancet Oncol"},{"issue":"2","key":"coi200103r35","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer.","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"issue":"11","key":"coi200103r36","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial.","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J Clin Oncol"},{"issue":"11","key":"coi200103r37","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1200\/JCO.2017.75.3335","article-title":"Quality of life during treatment with chemohormonal therapy: analysis of E3805 chemohormonal androgen ablation randomized trial in prostate cancer.","volume":"36","author":"Morgans","year":"2018","journal-title":"J Clin Oncol"},{"issue":"2","key":"coi200103r38","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.eururo.2015.11.005","article-title":"Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 Trial.","volume":"70","author":"Gravis","year":"2016","journal-title":"Eur Urol"},{"issue":"2","key":"coi200103r39","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/S1470-2045(17)30911-7","article-title":"Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.","volume":"19","author":"Chi","year":"2018","journal-title":"Lancet Oncol"},{"issue":"11","key":"coi200103r40","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/jjco\/hyy129","article-title":"Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-na\u00efve prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, Phase 3 study.","volume":"48","author":"Fukasawa","year":"2018","journal-title":"Jpn J Clin Oncol"},{"issue":"11","key":"coi200103r41","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/S1470-2045(19)30620-5","article-title":"Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study.","volume":"20","author":"Agarwal","year":"2019","journal-title":"Lancet Oncol"},{"issue":"12","key":"coi200103r42","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1093\/annonc\/mdz396","article-title":"Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial.","volume":"30","author":"Clarke","year":"2019","journal-title":"Ann Oncol"},{"issue":"5","key":"coi200103r43","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1093\/annonc\/mdy071","article-title":"What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? a STOPCAP systematic review and network meta-analysis.","volume":"29","author":"Vale","year":"2018","journal-title":"Ann Oncol"},{"issue":"3","key":"coi200103r44","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.eururo.2019.09.004","article-title":"Indirect comparisons of efficacy between combination approaches in metastatic hormone-sensitive prostate cancer: a systematic review and network meta-analysis.","volume":"77","author":"Sathianathen","year":"2020","journal-title":"Eur Urol"},{"issue":"suppl 1","key":"coi200103r45","first-page":"S139","article-title":"s current trial data sharing status conducive for evidence generation for personalized medicine: a failed attempt to conduct an individual pattient trial data network meta-analysis.","volume":"23","author":"Wang","year":"2020","journal-title":"Drugs Generics Org Pract"},{"key":"coi200103r19","author":"Sofia Dias","year":"2018"},{"key":"coi200103r31","volume-title":"Markov Chain Monte Carlo in Practice","author":"Gelman","year":"1996"},{"key":"coi200103r1","unstructured":"US Cancer Society. Prostate at a glance. Estimated new cases, 2020. Accessed May 28, 2020. https:\/\/cancerstatisticscenter.cancer.org\/#!\/cancer-site\/Prostate"},{"key":"coi200103r2","unstructured":"Cancer Stat Facts SEER. Prostate cancer. National Cancer Institute. Accessed May 28, 2020. https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html"},{"key":"coi200103r13","unstructured":"European Association of Oncology. Guidelines on prostate cancer. Full-text guidelines. Published 2020.? Accessed May 28, 2020 https:\/\/uroweb.org\/guidelin.e\/prostate-cancer\/"},{"key":"coi200103r14","unstructured":"National Comprehensive Cancer Network. Prostate cancer: version 2.2020. Accessed May 28, 2020. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf"},{"key":"coi200103r15","unstructured":"US Department of Veterans Affairs National Acquisition Center (CCST). Published 2019. Accessed October 27, 2019. https:\/\/www.vendorportal.ecms.va.gov\/nac\/Pharma\/List"},{"key":"coi200103r21","unstructured":"Rohatigi? A. WebPlotDigitizer, version 4.3. Published 2020. Accessed October 23, 2020. https:\/\/automeris.io\/WebPlotDigitizer"},{"key":"coi200103r26","unstructured":"Van Valkenhoef? G, Kuiper? J. gemtc: network meta-analysis using bayesian methods. R package, version 0.8-4. Updated August 10, 2020. Accessed May 28, 2020. https:\/\/CRAN.R-project.org\/package=gemtc"},{"key":"coi200103r27","unstructured":"R Foundation for Statistical Computing. R: a language and environment for statistical computing. Published 2019. Accessed May 28, 2020. https:\/\/www.R-project.org\/"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2774870\/jamaoncology_wang_2021_oi_200103_1615397490.23946.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T06:51:46Z","timestamp":1724309506000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2774870"}},"subtitle":["A Systematic Review and Network Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2021,3,1]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2020.6973","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3,1]]}}}